Results 1 - 25 from 64 for "antibiotice iasi"
-
Antibiotice Iasi Wants to Distribute RON13.8M Worth of Dividends
03.13.2025
Romanian drug manufacturer Antibiotice Iasi has proposed the distribution of RON13.8 million worth of dividends from the 2024 net profit reported on the basis of annual audited financial statements, more
-
Antibiotice Iasi 2024 Revenues Up 8% To RON693M, Net Profit Rises 23% To RON99M
02.26.2025
Romanian drug manufacturer Antibiotice Iasi in 2024 registered total revenues worth RON693 million, up 8%, and RON99 million net profit, 23% above the 2023 level. more
-
Antibiotice Iasi Aims to Invest RON850M by 2030
10.02.2024
Romanian drug manufacturer Antibiotice Iasi has a RON850 million investment plan until 2030, covered through a funding mix, made up of cohesion funds, state aid, PNRR funds and EIB loan, stated more
-
Antibiotice Iasi Reports RON74M Net Profit For H1/2024, Up 20% YoY
08.14.2024
Romanian-owned drug manufacturer Antibiotice Iasi (stock symbol: ATB) ended the first half of 2024 with net profit of RON74 million, up 20% on the year, while its revenue rose by 8% to RON380 million, more
-
Antibiotice Iasi Records 13% Revenue Growth in Q1/2024. Net Profit Climbs 68%
05.15.2024
Antibiotice Iasi, the largest Romanian-owned drug manufacturer, saw revenues reach an overall RON192.5 million level, 13% higher than in the year-earlier period. more
-
Antibiotice Iasi Eyes RON850M Investments by 2030
04.30.2024
Antibiotice Iasi, the largest Romanian-held drug maker, has a total RON850 million investment plan between 2023-2030 to reach RON1 billion turnover at the end of this period. more
-
Antibiotice Iasi Commissions 2.5 MW Photovoltaic Plant
03.28.2024
Pharma manufacturer Antibiotice Iasi has commissioned a 2.5 MW photovoltaic plant, with total investments in the project amounting to RON11.8 million, of which RON4.07 million were granted by the more
-
Antibiotice Iasi Wants to Cross RON100M Profit Threshold in 2024
03.25.2024
Antibiotice Iasi, the biggest Romanian-held drug manufacturer, wants to reach RON104 million net profit in 2024, up 28% from 2023, in line with its income and expenses budget. more
-
Antibiotice Iasi Seeks To Pay Dividends Of RON31M From 2023 Profit
03.14.2024
Pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) is summoning its shareholders to approve, among others, the distribution of RON31 million from the company's 2023 profit under the form of more
-
Antibiotice Iasi's Net Profit More Than Doubles YoY To RON80.7M In 2023
02.28.2024
Pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) ended 2023 with net profit of RON80.7 million, up 109.5% from 2022, and a turnover of RON600.8 million, up 7.2% on the year, in line with more
-
Antibiotice Iasi Launches New Vet Product Range
02.09.2024
Antibiotice Iasi, the largest Romanian-held pharma producer, is launching eight veterinary products in the range of nutritional supplements, complementing the company’s veterinary prescription more
-
Antibiotice Iasi Calls Shareholders To Approve Contracting RON35M Credit Facility From Banca Transilvania
01.25.2024
The Board of Directors of pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) announced in a stock market report on Thursday (Jan. 25, 2024) that it has called shareholders for a meeting on February more
-
Antibiotice Iasi Shares To Be Included In MSCI Indices Starting With 1st Trading Day Of Dec 2023
11.16.2023
The Bucharest Stock Exchange has announced Wednesday evening that the shares of Antibiotice (ATB.RO), the Romanian manufacturer of generic drugs, listed on the local capital market for 26 years, will more
-
Antibiotice Iasi Ends 9M 2023 with RON463.4M Turnover, Up 28%, RON76M Net Profit, More than Double the 9M 2022 Level
11.15.2023
Romanian state-owned pharma producer Antibiotice Iasi for the first nine months of 2023 reported RON463.4 million turnover, up 28%, and RON76 million net profit, more than doubled the RON30 million more
-
Antibiotice Iasi Shareholders OK EUR25M Funding from EIB
10.31.2023
The extraordinary general meeting of shareholders convened by drug maker Antibiotice Iasi on October 30 approved the signing of a financing contract worth EUR25 million euro, i.e. RON23 million more
-
Antibiotice Iasi Looks at New Export Markets
10.05.2023
Antibiotic Iasi, the biggest Romanian-held drug producer, is mulling new export markets, including Nordic ones, where it is trying to already develop its first local partnerships. more
-
Antibiotice Iasi Calls Shareholders To Approve EUR25M Financing Contract With The Romanian State
09.16.2023
Romanian state-owned pharmaceutical manufacturer Antibiotice (ATB.RO) has called shareholders for a general meeting on October 30, 2023 to secure approval for the conclusion of a financing contract more
-
SIF Oltenia Buys 2.4% Of Antibiotice Iasi Shares In RON9.3M Deal
05.18.2023
Antibiotice Iasi (ATB.RO), Romania’s most important generic drug manufacturer, on Thursday (May 18) informed the Bucharest Stock Exchange (BVB) that SIF Oltenia (SIF5.RO), its second largest more
-
Antibiotice Iasi Posts RON178M Sales in 1Q/2023, Up around 40%, Sees Net Profit Almost Triple To RON22M
05.12.2023
Romanian pharma producer Antibiotice Iasi ended the first quarter of 203 with RON178 million sales, up around 40%, and RON22 million net profit, almost triple the level of the year-earlier period. more
-
Antibiotice Iasi Ends 2022 With RON38.5M Net Profit, Up 29% YoY
02.27.2023
Romanian pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) said in a stock market report on Monday (Feb 27) that it ended 2022 with a net profit of RON38.5 million in 2022. up 28.6% versus 2021, more
-
Antibiotice Iasi Aims for RON580M Turnover and RON42M Profit in 2023
01.18.2023
Romanian pharmaceutical producer Antibiotice Iasi has budgeted RON580 million revenues for 2023, up 11% year-on-year and RON42 million net profit, 10% higher than in 2022. more
-
Enel X Romania To Build Solar Park For Antibiotice Iasi
12.13.2022
Enel X Romania, part of Enel X Global Retail, the advanced energy services division of Italy’s Enel Group, will build a photovoltaic (PV) park with a total installed capacity of 2.5 MW for Romanian more
-
Antibiotice Iasi Opens New Plant in Wake of EUR20M Investment
12.09.2022
Romanian pharmaceutical manufacturer Antibiotice Iasi is opening a new plant, in the wake of a EUR20 million investment, with a 50% higher production capacity than the existing unit. more
-
Antibiotice Iasi Revenue Up 47% YoY To RON361.7M In Jan-Sept 2022
11.11.2022
Romanian pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) said in a stock market report on Friday that it ended the first nine months of 2022 with sales revenue of RON361.7 million, up 47% on the more
-
Antibiotice Iasi Plans to Invest RON300M in Coming Years
10.06.2022
Romanian drug maker Antibiotice Iasi has budgeted RON300 million investments for the following years. more